DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of a new analysis of the pivotal Phase 2/3 N-MOmentum trial for UPLIZNA (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with NMOSD. These data are published in the May issue of Neurology Neuroimmunology...
Latest News
An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a...
DUBLIN – Horizon Therapeutics plc (Nasdaq: HZNP) today announced that a new post hoc analysis of the UPLIZNA N-MOmentum Phase 2/3 pivotal trial has been published in Multiple Sclerosis and Related Disorders showing that prior rituximab exposure did not impact the efficacy of UPLIZNA, and that UPLIZNA demonstrated comparable efficacy to trial participants...
Liverpool, UK – In people with a rare condition called light chain amyloidosis, light chain proteins—which are a component of antibodies—mutate and build up in different organs. In new research published in The FEBS Journal, investigators have identified and characterized an antibody fragment that can bind to abnormal light chains...
London, UK – Antibody treatment which activates the patient’s own immune system against cancer, known as immunotherapy, is increasingly being investigated as an alternative for chemotherapy and radiotherapy. This is because it specifically targets the cancer cells, which reduces the side effects seen with more conventional therapies. Tumours, such as...
OKLAHOMA CITY, OKLA. – Patients with diabetes face a host of potential health problems as they work to manage the chronic disease. Still, one concern that seems to weigh heavily is the risk of losing their sight through a condition known as diabetic retinopathy. Researchers at the University of Oklahoma...
Chicago, Ill. – Scientists from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago and colleagues found that an investigational protein replacement – recombinant human insulin-like growth factor 1 and its binding protein-3 (rhIGF-1/BP3) – protected neonatal mice from necrotizing enterocolitis (NEC), a deadly...
Scientists at Columbia University’s Mailman School of Public Health, the South African National Institute for Communicable Diseases of National Health Laboratory Service (NICD-NHLS), the U.S. Centers for Disease Control and Prevention, and Roche’s 454 Life Sciences Corporation have discovered the new virus responsible for a highly fatal hemorrhagic fever outbreak...
Laurel Hollow, NY – Metastatic cancer can be a devastating diagnosis. The cancer is spreading. It may travel to multiple organs in the body. This could mean more pain and ultimately, death.Unfortunately, just how cancer spreads remains unclear. But now, Cold Spring Harbor Laboratory (CSHL) Professor Adam Siepel and colleagues have a...
HOUSTON, TX – A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses...